Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of subcutaneous GR1501 in active lupus nephritis
CTR20230354Phase 2Active
- Sponsor
- Zhixiang Jintai
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of xeligekimab in lupus nephritis (LN), sponsored by Zhixiang Jintai. Started Feb 2023; status: active.
02
Drugs
xeligekimab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on CTR20230354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230354.